These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. Herviou L; Ovejero S; Izard F; Karmous-Gadacha O; Gourzones C; Bellanger C; De Smedt E; Ma A; Vincent L; Cartron G; Jin J; De Bruyne E; Grimaud C; Julien E; Moreaux J Clin Epigenetics; 2021 Sep; 13(1):174. PubMed ID: 34530900 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507 [TBL] [Abstract][Full Text] [Related]
6. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors. Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844 [TBL] [Abstract][Full Text] [Related]
7. Roles for the methyltransferase SETD8 in DNA damage repair. Xu L; Zhang L; Sun J; Hu X; Kalvakolanu DV; Ren H; Guo B Clin Epigenetics; 2022 Mar; 14(1):34. PubMed ID: 35246238 [TBL] [Abstract][Full Text] [Related]
8. The SETD8/PR-Set7 Methyltransferase Functions as a Barrier to Prevent Senescence-Associated Metabolic Remodeling. Tanaka H; Takebayashi SI; Sakamoto A; Igata T; Nakatsu Y; Saitoh N; Hino S; Nakao M Cell Rep; 2017 Feb; 18(9):2148-2161. PubMed ID: 28249161 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship studies of SETD8 inhibitors. Ma A; Yu W; Xiong Y; Butler KV; Brown PJ; Jin J Medchemcomm; 2014 Dec; 5(12):1892-1898. PubMed ID: 25554733 [TBL] [Abstract][Full Text] [Related]
10. SETD8 inhibition targets cancer cells with increased rates of ribosome biogenesis. Murga M; Lopez-Pernas G; Soliva R; Fueyo-Marcos E; Amor C; Faustino I; Serna M; Serrano AG; Díaz L; Martínez S; Blanco-Aparicio C; Antón ME; Seashore-Ludlow B; Pastor J; Jafari R; Lafarga M; Llorca O; Orozco M; Fernández-Capetillo O Cell Death Dis; 2024 Sep; 15(9):694. PubMed ID: 39341827 [TBL] [Abstract][Full Text] [Related]
11. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Takawa M; Cho HS; Hayami S; Toyokawa G; Kogure M; Yamane Y; Iwai Y; Maejima K; Ueda K; Masuda A; Dohmae N; Field HI; Tsunoda T; Kobayashi T; Akasu T; Sugiyama M; Ohnuma S; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R Cancer Res; 2012 Jul; 72(13):3217-27. PubMed ID: 22556262 [TBL] [Abstract][Full Text] [Related]
12. SETD8 involved in the progression of inflammatory bowel disease via epigenetically regulating p62 expression. Chen P; Zhu H; Mao Y; Zhuo M; Yu Y; Chen M; Zhao Q; Li L; Wu M; Ye M J Gastroenterol Hepatol; 2021 Oct; 36(10):2850-2863. PubMed ID: 33991018 [TBL] [Abstract][Full Text] [Related]
13. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Wakabayashi K; Okamura M; Tsutsumi S; Nishikawa NS; Tanaka T; Sakakibara I; Kitakami J; Ihara S; Hashimoto Y; Hamakubo T; Kodama T; Aburatani H; Sakai J Mol Cell Biol; 2009 Jul; 29(13):3544-55. PubMed ID: 19414603 [TBL] [Abstract][Full Text] [Related]
14. The emerging role of lysine methyltransferase SETD8 in human diseases. Milite C; Feoli A; Viviano M; Rescigno D; Cianciulli A; Balzano AL; Mai A; Castellano S; Sbardella G Clin Epigenetics; 2016; 8():102. PubMed ID: 27688818 [TBL] [Abstract][Full Text] [Related]
15. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Pei H; Zhang L; Luo K; Qin Y; Chesi M; Fei F; Bergsagel PL; Wang L; You Z; Lou Z Nature; 2011 Feb; 470(7332):124-8. PubMed ID: 21293379 [TBL] [Abstract][Full Text] [Related]
16. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC. Li X; Liu Z; Xia C; Yan K; Fang Z; Fan Y Cancer Lett; 2022 Feb; 527():150-163. PubMed ID: 34942305 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. Veschi V; Liu Z; Voss TC; Ozbun L; Gryder B; Yan C; Hu Y; Ma A; Jin J; Mazur SJ; Lam N; Souza BK; Giannini G; Hager GL; Arrowsmith CH; Khan J; Appella E; Thiele CJ Cancer Cell; 2017 Jan; 31(1):50-63. PubMed ID: 28073004 [TBL] [Abstract][Full Text] [Related]
18. The histone lysine methyltransferase SETD8 regulates angiogenesis through HES-1 in human umbilical vein endothelial cells. Choi DK; Kim YK; Park SW; Lee H; Lee S; Kim SA; Kim SJ; Lee J; Kim W; Min SH; Yu JH Sci Rep; 2020 Jul; 10(1):12089. PubMed ID: 32694555 [TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase Setd8 alters the chromatin landscape and regulates the expression of key transcription factors during erythroid differentiation. Myers JA; Couch T; Murphy Z; Malik J; Getman M; Steiner LA Epigenetics Chromatin; 2020 Mar; 13(1):16. PubMed ID: 32178723 [TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin. Driskell I; Oda H; Blanco S; Nascimento E; Humphreys P; Frye M EMBO J; 2012 Feb; 31(3):616-29. PubMed ID: 22117221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]